Checked
Qiagen N.V.
NYSE: QGEN · Biological Products, (No Diagnostic Substances) · Pl Venlo, Netherlands
- Revenue
- $2.09B
- +5.7% vs. prior year
- Net income
- $424.9M
- 20.3% net margin
- Total assets
- $6.28B
- Diluted EPS
- $1.94
Company details
As reported to the SEC
- SEC CIK
- 1015820
- Stock
- NYSE: QGEN
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- Pl Venlo, Netherlands
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Last annual report
- 03/20/2026
Formerly: QIAGEN NV (until 02/14/2020)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Gross profit | $1.3B | $967.4M | $1.23B | $1.38B | $1.45B |
| Operating income | $465.9M | $97.71M | $409.9M | $531.5M | $630.1M |
| Net income | $424.9M | $83.59M | $341.3M | $423.2M | $512.6M |
| Diluted earnings per share | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 |
| Research and development | $187.5M | $193.5M | $198.5M | $189.9M | $190M |
| Total assets | $6.28B | $5.69B | $6.12B | $6.29B | $6.15B |
| Shareholders' equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.1B |
| Cash and cash equivalents | $839M | $663.6M | $668.1M | $730.7M | $880.5M |
| Long-term debt | $1.65B | $839.7M | $921.8M | $1.47B | $1.09B |
| Cash from operations | $654.3M | $673.6M | $459.5M | $715.3M | $639M |
| Capital expenditures | $201M | $167.2M | $149.7M | $129.2M | $189.9M |
Federal and state records filed under the name Qiagen N.V.
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Qiagen LLCGermantown, MD | 1 | 0 |
FDA recalls
Recalls of food, drugs and devices reported to the FDA
Swipe the table sideways to see more columns.
| Product | Class | Started |
|---|---|---|
| EZ1 DSP Virus Kit (48), IVD, REF 62724 intended for in vitro diagnostic use. | Class II | 05/28/2018 |
Recent filings
95 recent filings on record
Swipe the table sideways to see more columns.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
| BIO-TECHNE CorpTECH | Minneapolis, MN | $1.22B | $181.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Qiagen N.V.'s CIK number?
- Qiagen N.V.'s SEC Central Index Key (CIK) is 1015820.
- What is Qiagen N.V.'s stock ticker?
- Qiagen N.V. trades as NYSE: QGEN.
- What was Qiagen N.V.'s revenue?
- Qiagen N.V. reported revenue of $2.09B for the fiscal year ended Dec 31, 2025, +5.7% from the year before.
- When does Qiagen N.V.'s fiscal year end?
- Qiagen N.V.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Qiagen N.V. headquartered?
- Qiagen N.V.'s principal executive office on file with the SEC is in Pl Venlo, Netherlands.
- Does Qiagen N.V. sponsor H-1B visas?
- Department of Labor records show 1 certified H-1B filings and 0 certified PERM filings under the name Qiagen N.V.
- Has Qiagen N.V. had any FDA recalls?
- The FDA lists 1 recall with Qiagen N.V. as the recalling firm. The latest started May 28, 2018.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026